{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T21:41:25Z","timestamp":1771796485571,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.canrad.2012.12.006","type":"journal-article","created":{"date-parts":[[2013,3,15]],"date-time":"2013-03-15T21:13:36Z","timestamp":1363382016000},"page":"183-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["\u00c9tude prospective monocentrique de la toxicit\u00e9 et de l\u2019efficacit\u00e9 du trastuzumab concomitant \u00e0 la radioth\u00e9rapie"],"prefix":"10.1016","volume":"17","author":[{"given":"J.","family":"Jacob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Belin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gobillion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Daveau-Bergerault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dendale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Beuzeboc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Campana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-A.","family":"Bollet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fourquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.M.","family":"Kirova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2012.12.006_bib0005","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.canrad.2012.12.006_bib0010","first-page":"1113","article-title":"Sensitization of breast cancer cells to radiation by trastuzumab","volume":"2","author":"Liang","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.canrad.2012.12.006_bib0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.canrad.2012.12.006_bib0020","first-page":"5","article-title":"Perceptions of herceptin: a monoclonal antibody for the treatment of breast cancer","volume":"14","author":"Dillman","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.canrad.2012.12.006_bib0025","first-page":"1347","article-title":"Monoclonal antibody to HER-2\/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene","volume":"59","author":"Pietras","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.canrad.2012.12.006_bib0030","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2\u00a0for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2012.12.006_bib0035","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER-2\u00a0positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2012.12.006_bib0040","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2012.12.006_bib0045","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","article-title":"Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study","volume":"28","author":"Untch","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2012.12.006_bib0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.breast.2003.09.002","article-title":"Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer","volume":"13","author":"Suter","year":"2004","journal-title":"Breast"},{"key":"10.1016\/j.canrad.2012.12.006_bib0055","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials","volume":"366","author":"Clarke","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2012.12.006_bib0060","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.canrad.2009.02.008","article-title":"Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy","volume":"13","author":"Kirova","year":"2009","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2012.12.006_bib0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2010.08.013","article-title":"The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study","volume":"47","author":"Caussa","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2012.12.006_bib0070","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.ijrobp.2004.08.051","article-title":"Breast radiotherapy in the lateral decubitus position: a technique to prevent heart and lung irradiation","volume":"61","author":"Campana","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2012.12.006_bib0075","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ijrobp.2007.05.007","article-title":"Postmastectomy electron beam chest wall irradiation in women with breast cancer: a clinical step toward conformal electron therapy","volume":"69","author":"Kirova","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2012.12.006_bib0080","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0167-8140(00)00152-3","article-title":"Cardiac and lung complication probabilities after breast cancer irradiation","volume":"55","author":"Hurkmans","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2012.12.006_bib0085","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0360-3016(02)03741-0","article-title":"The impact of central lung distance, maximal heart distance, and radiation technique on the volumetric dose of the lung and heart dose for intact breast radiation","volume":"54","author":"Kong","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2012.12.006_bib0090","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","article-title":"Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831","volume":"27","author":"Halyard","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2012.12.006_bib0095","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/annonc\/mdn029","article-title":"Concurrent trastuzumab with adjuvant radiotherapy in HER-2\u00a0positive breast cancer patients: acute toxicity analyses from the French multicentric study","volume":"19","author":"Belkac\u00e9mi","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2012.12.006_bib0100","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac events in the Herceptin Adjuvant (HERA) Trial","volume":"28","author":"Procter","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2012.12.006_bib0105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.radonc.2008.09.003","article-title":"Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study","volume":"90","author":"Shaffer","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2012.12.006_bib0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.radonc.2009.04.009","article-title":"Concurrent trastuzumab \u2013 internal mammary node irradiation for HER2\u00a0positive breast cancer: \u201cIt hurts to be on the cutting edge\u201d","volume":"94","author":"Belkac\u00e9mi","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2012.12.006_bib0115","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.ijrobp.2008.06.970","article-title":"Radiation treatments may contribute to the development of cardiac dysfunction in breast cancer patients treated with chemotherapy and trastuzumab","volume":"72","author":"Alm El-Din","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2012.12.006_bib0120","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2012.12.006_bib0125","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.1037","article-title":"Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment","volume":"24","author":"Harris","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2012.12.006_bib0130","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ijrobp.2007.05.034","article-title":"Cardiac exposures in breast cancer radiotherapy: 1950s\u20131990s","volume":"69","author":"Taylor","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2012.12.006_bib0135","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2008.05.066","article-title":"Estimating cardiac exposure from breast cancer radiotherapy in clinical practice","volume":"73","author":"Taylor","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2012.12.006_bib0140","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321813000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321813000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:20:35Z","timestamp":1761135635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321813000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S1278321813000061"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2012.12.006","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9tude prospective monocentrique de la toxicit\u00e9 et de l\u2019efficacit\u00e9 du trastuzumab concomitant \u00e0 la radioth\u00e9rapie","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2012.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}